Athira Pharma (ATHA)

• Market cap: $16.4M
• 1 day: -0.24%
• 5 days: 2.46%
• 1 month: 0.48%
• 3 months: 9.47%
• 6 months: 47.52%
• Year to date: -24.36%
• 1 year: -2.8%
• 5 years: -97.71%
• 10 years: -97.57%
• Sector: Healthcare
• Industry: Biotechnology

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Employees: 26